Cancer Therapy : Preclinical Dasatinib Plus Nutlin-3 Shows Synergistic Antileukemic Activity in Both p 53 wild-type and p 53 mutated B Chronic Lymphocytic Leukemias by Inhibiting the Akt Pathway
暂无分享,去创建一个
A. Cuneo | P. Secchiero | G. Zauli | S. Marmiroli | G. Rigolin | R. Voltan | E. Melloni | R. Bosco